A novel hepatitis B vaccination regimen for adolescents

liver411

Vaccine, Vol. 20 (29-30) (2002) pp. 3472-3476
Crown copyright © 2002 Published by Elsevier Science Ltd. All rights reserved.
PII: S0264-410X(02)00346-8

A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart
Leon G. Heron a * [email protected] , Kerry G. Chant a and Bin B. Jalaludin b
a South Western Sydney Public Health Unit, Liverpool Hospital, Locked Bag 7017, Sydney, NSW 1871, Australia
b South Western Sydney Epidemiology Unit, Liverpool Hospital, Sydney, NSW, Australia
Received 1 February 2002; received in revised form 22 April 2002; accepted 5 July 2002

Abstract
Background: Two- and three-dose hepatitis B vaccinations for adolescents are usually administered using dosing schedules of 6 months duration. This does not suit all circumstances. A 12-month schedule would be useful in schools and settings where only annual vaccination is the most practical option.

Aim: To examine the efficacy of a 12-month dosing interval for two-dose hepatitis B vaccination of adolescents.

Subjects: Four hundred and fifty-eight healthy first-year high school (Year 7) students.

Vaccination regimen: Engerix-B (GlaxoSmithKline Biologicals) 20µg: two doses, 12 months apart.

Serum collection: #1, same day as first vaccine dose given; #2, >1 month after second vaccine dose.

Results: Of the 458 children: 15 did not provide serum #1, 17 had prior vaccination, 2 had prior infection, 18 moved, 7 failed to provide serum #2, 12 withdrew (only 1 cited vaccine adverse reactions as the reason). Three hundred and eighty-seven (210 males, 177 females) aged 11.8-14.2 years (mean: 12.9±0.42 years) at entry completed both injections 321-381 days (mean: 359±10.7 days) apart and supplied serum #2, 30-57 days (mean: 41±5.6 days) after the second vaccine dose.

Anti-HBs responses: 379 of the 387 subjects (97.9%; 95% CI: 95.9-99.1%) achieved anti-HBs 10mIU/ml (range 10-170,460mIU/ml, geometric mean concentration (GMC) 4155mIU/ml95% CI of mean: 3381-5106mIU/ml). Sex was the only determinant of anti-HBs concentration (206 males: GMC 3073mIU/ml95% CI: 2285-4134mIU/ml; 173 females: GMC 5944mIU/ml95% CI: 4508-7851mIU/ml; P=0.001).

Conclusion: A high seroprotection rate and GMC were achieved using two 20µg doses of Engerix-B administered 12 months apart. These results are similar to those achieved by others using 6-month three- and two-dose regimens in adolescents.

Keywords: Hepatitis B vaccine; Two-dose vaccination; Twelve-month schedule; Adolescents
*Corresponding author. Tel.: +61-2-9828-5944; fax: +61-2-9828-5955.

Full text supplied by [ScienceDirect]

© Copyright 2002, Elsevier Science, All rights reserved.

茄子

(我完成任务了，感觉没什么用吧）

一种青少年用新型乙肝疫苗：12个月分两剂施用

作者： Leon G. Heron a * [email protected] , Kerry G. Chant a and Bin B. Jalaludin b
地址a： South Western Sydney Public Health Unit, Liverpool Hospital, Locked Bag 7017, Sydney, NSW 1871, Australia
地址b： South Western Sydney Epidemiology Unit, Liverpool Hospital, Sydney, NSW, Australia
Received 1 February 2002; received in revised form 22 April 2002; accepted 5 July 2002
Abstract摘要
背景：青少年接种乙肝疫苗通常要以6个月为期2到3剂才能完成。这种方法不能适合各类环境。12个月接种期适合一些学校等一些以年为最佳接种期的机构。
目标：检验青少年12个月接种两次乙肝疫苗的功效。
受检人员：458名高一学生。
疫苗用法: Engerix-B (GlaxoSmithKline Biologicals) 20µg: 两剂, 12个月分用.
血清采集: #1, 首次接种疫苗同一天； #2, 第二次接种疫苗一个月后。
结果：458个学生中15个没能提供#1血清，17个已经事前接种过疫苗，2个过去感染过，18人迁移，7人没能提供#2血清，12人退出（只有一人是由于接种副作用引起的）。387人（210男生，177女生）11.8-14.2岁（平均值12.9±0.42年）在321-381天内(均值359±10.7天)分次完成了注射，并在第二次接种后30-57天（均值41±5.6天）提供了血清。
抗-HBs 反应：387人中有379人（97.9%; 95% CI: 95.9-99.1%）获得了抗体，10mIU/ml（范围在10-170， 460mIU/ml， 几何平均浓度（GMC）集中在4155mIU/ml 占95% 均值CI在3381mIU/ml-5106mIU/ml）。性别是唯一的影响抗体浓度因素（206 males: GMC 3073mIU/ml95% CI: 2285-4134mIU/ml; 173 females: GMC 5944mIU/ml95% CI: 4508-7851mIU/ml; P=0.001）。
结论：采用12个月分两期每次接种20µg Engerix-B可以获得高血清保护率和抗体几何浓度（GMC）。这个结果与通过在青少年中采用2到3次间隔6个月的接种结果相近。

可可

呵呵..给你的任务轻一点,先练练手. 下次可就不一样了噢.

谢谢!

乙肝疫苗的重点防治对象是在青少年.所以是很重要的.